semaglutide hearing loss Severe - Recommendations for Fitting Amplification The Risk of Vestibular Disorders

FDA approves Wegovy for MASH with moderate to advanced liver fibrosis owenhaskins Aug 18, 2025 2 min read The FDA has approved Wegovy (semaglutide) injection 2.4 mg to treat adults with MASH with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver, in conjunction with a reduced calorie diet and increased physical activity

While there are no absolute dietary restrictions, certain dietary approaches may help minimize side effects

Scientific References Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled pen Summary of Product Characteristics (SmPC)

The landmark SUSTAIN clinical trial series evaluated semaglutide in thousands of patients with type 2 diabetes, providing data on various metabolic parameters including lipid profiles